Gilead Summits Takeback Of Trodelvy Rights In Deal With Everest

 
• By Alaric DeArment

Deal Snapshot: Through subsidiary Immunomedics, Gilead will pay $280m up front to gain the remaining global rights to the drug, at a time when Everest’s business model has encountered some difficulties in China.

Gilead said it would buy rights to Trodelvy from Everest, which had in-licensed them from Immunomedics in 2019 • Source: Shutterstock

More from Deals

More from Business